Trial reportEuropean journal of pediatrics1991
The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies.
Trial report in European journal of pediatrics, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomised controlled trials.Archives of disease in childhood · 2000Pooled it
- The first randomized controlled trial in pediatric nephrology: the history of the International Study of Kidney Disease in Children (ISKDC).Pediatric nephrology (Berlin, Germany) · 2023Trial
- Calcium and vitamin D for osteoprotection in children with new-onset nephrotic syndrome treated with steroids: a prospective, randomized, controlled, interventional study.Pediatric nephrology (Berlin, Germany) · 2014Trial
- Childhood nephrotic syndrome at the University of Abuja Teaching Hospital, Abuja, Nigeria: a preliminary report supports high steroid responsiveness.Sudanese journal of paediatrics · 2019Article
- Initial steroid regimen in idiopathic nephrotic syndrome can be shortened based on duration to first remission.Korean journal of pediatrics · 2015Article
- Glucocorticoid effects on changes in bone mineral density and cortical structure in childhood nephrotic syndrome.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2013Article
- Significance of electron dense deposits in patients with minimal change nephrotic syndrome.Korean journal of pathology · 2012Article
- Clinical course and outcome of children with steroid-sensitive nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2011Article
- Ten year experience of pediatric kidney biopsies from a single center in Pakistan.Indian journal of nephrology · 2010Article
- Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2009Article
- Treatment of the first episode of nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2006Article
- Up-regulation of interleukin-2 mRNA in children with idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2004Article
- The management of idiopathic nephrotic syndrome in children.Paediatric drugs · 2003Review
- Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood.Pediatric nephrology (Berlin, Germany) · 1994Article
- Glomerular volume and renal function in children with different types of the nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 1994Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minimal change nephrotic syndrome (MCNS) is the most frequent type of nephrotic syndrome in childhood. Treatment aims to induce remission, prevent relapses and avoid side-effects. MCNS is responsive to immunosuppressive therapy with glucocorticosteroids, alkylating drugs and cyclosporine A. From results of multicentre controlled studies it became evident that the initial treatment with prednisone should be intensive, i.e. for 12 weeks, in order to reduce the risk of subsequent relapses. Treatment of relapses should be standardized in order to categorize the patient's disease for further treatment. In case "frequent relapsers" develop signs of steroid-toxicity, they should be treated with alkylating drugs: frequent relapsers without steroid dependency with cyclophosphamide or chlorambucil for 8 weeks, steroid-dependent cases with cyclophosphamide for 12 weeks. If frequent relapses re-occur after cytotoxic drug therapy, treatment with cyclosporine A should be considered. Starting dose is 100-150 mg/m2 per day and needs to be adjusted to the whole blood trough level. Treatment with cyclosporine A must be strictly controlled in order to avoid chronic nephrotoxicity. Cyclosporine A does not cure MCNS. It is only effective as long as it is administered; therefore long-lasting treatment is necessary in most cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.